{"name":"Rachel Sanborn","slug":"rachel-sanborn","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Consolidation durvalumab","genericName":"Consolidation durvalumab","slug":"consolidation-durvalumab","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Consolidation durvalumab","genericName":"Consolidation durvalumab","slug":"consolidation-durvalumab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPY0QtQjNENmJES2RUTW5RZTQ4cC1mTHZqaDNfVk9yejJ0a0NhY1dLb2MxdW5rLWVPaEFJZWhycmFFNldLXzA1TWR0MlU0bHYzam9kUldtWDlCV3pWM0J4Q2FUQTkyZldwRnFLTHNNcWZaY2ptOEd3SXl6MkFZbmNwWTEzWUlLOXVnb3FIZl8wZUZaXzZNbjFNbDZzY0V4YjNWVTVVQWJzWnk4blBsM1lwWF9mUXEyYjlJRjdXMm1QM2V1Y1k?oc=5","date":"2025-08-08","type":"trial","source":"OncLive","summary":"Dr Sanborn on Early Efficacy and Safety Data With Sigvotatug Vedotin Plus Pembrolizumab in NSCLC - OncLive","headline":"Dr Sanborn on Early Efficacy and Safety Data With Sigvotatug Vedotin Plus Pembrolizumab in NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5pbnNMYmZHX2NnLUpfWG1ldTZWdjIzd3pLRTlqaXJDY19KSjFvMnNBdXBmVktEdV93cDdham01T3hRNzJZWFFsRlRIZFFvZXNPRWhiWTZmZ0RSc3J6WlhZ?oc=5","date":"2024-06-13","type":"trial","source":"Nature","summary":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial - Nature","headline":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}